{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:23:53Z","timestamp":1781101433934,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004324","name":"OSI Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009032","name":"Pfizer Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clgc.2022.04.018","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T02:40:26Z","timestamp":1651718426000},"page":"415-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma"],"prefix":"10.1016","volume":"20","author":[{"given":"Zizhen","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan D.","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Strother","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunqiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Agnor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz M.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4259-1123","authenticated-orcid":false,"given":"Christopher W.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clgc.2022.04.018_bib0001","doi-asserted-by":"crossref","first-page":"680s","DOI":"10.1158\/1078-0432.CCR-06-1865","article-title":"The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma","volume":"13","author":"Kaelin","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clgc.2022.04.018_bib0002","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/01.ju.0000074870.54671.98","article-title":"Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas","volume":"170","author":"Na","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.04.018_bib0003","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.04.018_bib0004","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.04.018_bib0005","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0046-8177(97)90198-2","article-title":"Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma","volume":"28","author":"Moch","year":"1997","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clgc.2022.04.018_bib0006","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1158\/0008-5472.CAN-05-0169","article-title":"Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-\/- renal cancer","volume":"65","author":"Smith","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2022.04.018_bib0007","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1200\/JCO.2005.01.8234","article-title":"Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.04.018_bib0008","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2007.11.5154","article-title":"Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer","volume":"25","author":"Bukowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.04.018_bib0009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2022.04.018_bib0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.04.018_bib0011","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.04.018_bib0012","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.04.018_bib0013","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.04.018_bib0014","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.04.018_bib0015","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1200\/JCO.2008.18.8821","article-title":"Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317","volume":"27","author":"Gordon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.04.018_bib0016","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4143\/crt.2019.086","article-title":"Bevacizumab plus Erlotinib Combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: a multicenter retrospective analysis in Korean patients","volume":"51","author":"Choi","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clgc.2022.04.018_bib0017","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1200\/JCO.2020.38.15_suppl.5004","article-title":"Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer","volume":"38","author":"Ramaprasad Srinivasan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.04.018_bib0018","unstructured":"Available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf (Accessed on 3\/5\/2021)."},{"key":"10.1016\/j.clgc.2022.04.018_bib0019","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0959-8049(14)70131-5","article-title":"5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib","volume":"50","author":"Srinivasan","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2022.04.018_bib0020","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2004.11.061","article-title":"Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer","volume":"22","author":"Rowinsky","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.04.018_bib0021","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1023\/A:1025472712456","article-title":"Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma","volume":"21","author":"Drucker","year":"2003","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clgc.2022.04.018_bib0022","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1158\/1078-0432.CCR-04-0310","article-title":"A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma","volume":"10","author":"Dawson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2022.04.018_bib0023","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00280-005-0070-z","article-title":"A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma","volume":"57","author":"Jermann","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2022.04.018_bib0024","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1200\/JCO.2007.14.5029","article-title":"Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial","volume":"26","author":"Ravaud","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.04.018_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12859-018-2093-6","article-title":"Prediction of sensitivity to gefitinib\/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis","volume":"19","author":"Zou","year":"2018","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.clgc.2022.04.018_bib0026","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s11095-005-7094-2","article-title":"EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients","volume":"22","author":"Sakaeda","year":"2005","journal-title":"Pharm Res"},{"key":"10.1016\/j.clgc.2022.04.018_bib0027","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.7150\/thno.38346","article-title":"The combination of bevacizumab\/Avastin and erlotinib\/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor","volume":"10","author":"Gr\u00e9pin","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.clgc.2022.04.018_bib0028","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/annonc\/mds524","article-title":"Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy","volume":"24","author":"Wheler","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.04.018_bib0029","first-page":"797","article-title":"The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma","volume":"34","author":"Do","year":"2009","journal-title":"Int J Oncol"},{"key":"10.1016\/j.clgc.2022.04.018_bib0030","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm.4401","article-title":"Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma","volume":"23","author":"Tan","year":"2017","journal-title":"Nat Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:37Z","timestamp":1761564937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322000945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1558767322000945"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.04.018","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}